¤E¤Q¤@¦~«×¤º¬ì±M¬ìÂå®v¦Ò¸Õµ§¸ÕÃD -- ¦å²G¬ì

(D) 1.¥Ø«e½Ã¥Í¸p¤w®Ö­ã¤@ºØ¤fªA¹TÓi»Ä¿EúC§í¨î¾¯¡]tyrosine kinase inhibitor¡^STI-571¡]¤SºÙGleevec©Îimtinib mesylate¡^¨Ï¥Î¦b¯e¯fªºªvÀø¤W¡A½Ð°Ý¤U¦C¨º¤@ºØ¯e¯f¥i¥H¥Î¦¹Ãıo¨ì¤£¿ùªº®ÄªG¡H
A.±a¦³¬V¦âÅ鲧±`t(8;21)¤§«æ©Ê°©Åè©Ê¥Õ¦å¯f
B.±a¦³¬V¦âÅ鲧±`inv(16)¤§«æ©Ê°©Åè©Ê¥Õ¦å¯f
C.±a¦³¬V¦âÅ鲧±`t(4;11)¤§«æ©Ê²O¤ÚªÞ²Ó­M¥Õ¦å¯f
D.±a¦³¬V¦âÅ鲧±`t(9;22)¤§ºC©Ê°©Åè©Ê¥Õ¦å¯f
E.±a¦³¬V¦âÅ鲧±`13q¤§ºC©Ê²O¤Ú²Ó­M¥Õ¦å¯f
 
(C) 2.¤@65·³¯f±w¦]¬°µo¿N¦í°|¡A©â¦åÀˬdµo²{¥Õ¦å²y¼Æ¬°1,100/£gL¡Aneutrophils 10%¡Alymphocytes 80%¡Aeosinophils 1%¡A monocytes 9%¡A¬õ¦å²y¤Î¦å¤pªO¼Æ¥Ø¥¿±`¡C¯f¤H³ÌªñªA¥ÎªºÃĪ«¦p¤U¡A¨ä¤¤³Ì¥i¯à³y¦¨¦¹¦å²G¬ÛÅܤƪºÃĪ«¬O¨º¤@­Ó¡H
A.Digoxin
B.Furosemide
C.Ticlopidine
D.Glipizide
E.Metformin
 
(D) 3.¤@¯f¤H¤W¸¡³¡¤£¾A¡A¸g­GÃè¤Î¤Á¤ùÀˬdµo²{­G¤º¦³MALT²O¤Ú½F¡]mucosa-associated lymphoid tumor¡^¡A¨ä¥LÀˬd¨ÃµL²§±`¡C½Ð°Ýªì¨B¹ï¦¹¯f¤H³Ì¾A·íªº³B¸m¬°¡G
A.­G¤Á°£
B.©ñ®g½uªvÀø
C.¤Æ¾ÇªvÀø
D.¨Ï¥ÎªvÀø«Õªù±ìµßªºÃĪ«
E.­G¤Á°£¥[©ñ®g½uªvÀø
 
(B) 4.¤@35·³°ü¤k¡AµL¥þ¨­©Ê¯e±w¡A¦b¨Ò¦æÅéÀˮɡAµo²{¶gÃä¦å¤¤¦å¬õ¯À¬°10.2gm/dL¡AMCV¬°70fL¡A¥Õ¦å²y¤Î¦å¤pªO¼Æ¥¿±`¡C¯f¤H5¦~«eÅéÀˮɦå¬õ¯À­È¬°12.5gm/dL¡AMCV¬°88fL¡C½Ð°Ý¦¹°ü¤k¥Ø«e³Ì¥i¯à¬O¦³¤°»ò¯f¡H
A.®ü¬v©Ê³h¦å
B.¯ÊÅK©Ê³h¦å
C.¦A¥Í¤£¨}©Ê³h¦å
D.Vit B12¯Ê¥F©Ê³h¦å
E.·»¦å©Ê³h¦å
 
(A) 5.¤U¦C±¡ªp³Ì¤£¥i¯à¤Þ°_¦å¤pªO¼Æ¥Ø­°§CªÌ¬°¡G
A.¨Ï¥Îepinephrine
B.¨Ï¥Îheparin
C.¨xµw¤Æ
D.·»¦å©Ê§¿¬r¯g­Ô¸s¡]hemolytic uremic syndrome¡^
E.¥þ¨­©Ê¬õ´³©Ê¯T½H¡]systemic lupus erythematosus¡^
 
(B) 6.¤@¯f¤Hªº°©Åè©Ù¤ù¦p¹Ï©Ò¥Ü¡A½Ð°Ý³o¦ì¯f¤H±o¤F¤°»ò¯f¡H
A.ºC©Ê°©Åè²Ó­M¥Õ¦å¯f
B.«æ©Ê°©Åè©Ê¥Õ¦å¯f
C.ºC©Ê²O¤Ú²Ó­M¥Õ¦å¯f
D.«æ©Ê²O¤ÚªÞ²Ó­M¥Õ¦å¯f
E.²O¤Ú½F°©Åè«I¥Ç
 
(B) 7.§N­á¨H¾ý«~¡]cryoprecipitate¡^¤º§t¦³³¡¤À¾®¦å¦]¤l¡A¥i¥Î¨ÓªvÀø»Ý­nªº¯f±w¡A¤U¦C¯f¤H¤¤¦óªÌ¨Ï¥Î§N­á¨H¾ý«~¨S¦³À°§U¡H
A.A«¬¦å¤Í¯f±w
B.B«¬¦å¤Í¯f±w
C.Von-Willebrand¤ó¯f±w
D.ÅÖºû³J¥Õ­ì¡]fibrinogen¡^¯Ê¥F¯f±w
E.ÅÖºû³J¥Õ­ì²§±`¯f±w
 
(A) 8.¤@25·³¯f¤H³Q¶EÂ_¬°«æ©Ê²O¤ÚªÞ²Ó­M¥Õ¦å¯f¡A¶O«°¬V¦âÅ鶧©Ê¡C½Ð°Ý¹ï¦¹¯f¤H³Ì¾A·íªº³B¸m¬°¦ó¡H
A.¦b¥S§Ì©n©f¤¤´M§ä¤HÃþ¥Õ¦å²y§Ü­ì»P¯f¤H¬Û¦XªÌ¡A¦b¨Ï¥Î¤Æ¾ÇªvÀø¹F¨ì½w¸Ñ«á¡A§Y¶i¦æ²§Åé³y¦å·F²Ó­M²¾´Ó¡C
B.¨Ï¥Î¤Æ¾ÇªvÀø¹F¨ì½w¸Ñ«á¡A¶i¦æ¦ÛÅé³y¦å·F²Ó­M²¾´Ó¡C
C.¨Ï¥Î¤Æ¾ÇªvÀø¹F¨ì½w¸Ñ«á¡A¦A§@°ª¾¯¶q¥[±j©Ê¤Æ¾ÇªvÀø¡A®ÄªG»P³y¦å·F²Ó­M²¾´Ó®t¤£¦h¡C
D.¨Ï¥Î¤Æ¾ÇªvÀø¹F¨ì½w¸Ñ«á¡A¦A§ï¥Î¤fªAºû«ù©Ê¤Æ¾ÇªvÀø¡C
E.¨Ï¥Î¤Æ¾ÇªvÀø¹F¨ì½w¸Ñ«á¡A¥i°±ÃıK¤Á°lÂÜ¡C
 
(E) 9.¤U¦C¨º¨Ç­ì¦]¥i³y¦¨¦hµo©Ê°©Åè½F¯f¤HªºµÇŦ¥\¯à»Ùê¡H1. §K¬Ì²y³J¥Õ»´Ãì¡]light chain¡^¥Ñ¤p«K¤¤±Æ¥X2. °ª¶t¦å¯g3. °ª§¿»Ä¦å¯g4. Ãþ¾ý¯»¡]amyloid¡^¨H¿n
A.1+2
B.1+3
C.2+3
D.1+2+3
E.1+2+3+4
 
(C) 10.«æ©Ê«e°©Åè²Ó­M¥Õ¦å¯f¡]acute promyelocytic leukemia¡^¯f¤H¨Ï¥Î¥þ¤Ï¦¡ºû¥Ò»Ä¡]all-trans retinoic acid¡^ªvÀø«á¡A¦³¥i¯à¥X²{ºû¥Ò»Ä¯g­Ô¸s¡]retinoic acid syndrome¡^½Ð°Ý¤U¦C¦óªÌ¬O¦¹¯g­Ô¸s±`¨£ªº¯gª¬¡H1. µo¿N2. ªÍ®û¼í¤Þ°_©I§l«æ«P3. Åöíw
A.1
B.2
C.1+2
D.1+3
E.2+3
 


< ¤E¤Q¤@¦~«×¸ÕÃD¥Ø¿ý >